ThyroSeq® GC - the most comprehensive NGS
test for thyroid nodules available

ThyroSeq® Genomic Classifier (GC) test utilizes next-generation sequencing to analyze DNA and RNA of 112 thyroid-related genes for four main classes of molecular alterations, including mutations, gene fusions, copy number alterations, and gene expression alterations

The results are processed by a unique Genomic Classifier (GC) and reported as Positive or Negative1

112 Thyroid-Related Genes

Genes 112 Revised 02

Including all expressed (BRAF, RAS) and not expressed (TERT) variants important for thyroid cancer

Genes 112 Revised 03

Including known and novel types of RET, NTRK, ALK, and other fusions

Genes 112 Revised Alteration 04

Critical for diagnosis of Hürthle cell nodules and follicular carcinomas

Genes 112 Revised 05

To diagnose medullary carcinoma, non-thyroidal nodules, and additional classes of thyroid cancer

In one test, ThyroSeq® Classifier:

 

  • Confidently rules out cancer and prevents unneeded surgeries in 61-67% of patients with indeterminate cytology nodules 2-8

 

 

 

 

 

 

ThyroSeq® Test Workflow

 

Diagnostic Utility Chart R1

 

References:

1. Nikiforova MN, et al. Cancer. 2018. 2. Steward DL, et al. JAMA Oncol. 2018. 3. Chin PD, et al. Endocrin Pathol. 2020. 4. Jug R, et al. Cancer Cytopathol. 2020. 5. Guan H, et al. Thyroid. 2020. 6. Chen T, et al. Thyroid. 2020. 7. Schatz-Siemers N, et al. Diagn Cytopathol. 2019. 8. Desai D, et al. Cancer Cytopathol. 2020.